A revolutionary approach to cancer treatment promises to change the face of medicine. A new form of immunotherapy administered in an injection lasting less than five minutes appears to offer the same effectiveness as conventional, long-term treatments.
This treatment is already being applied in the United Kingdom, within the framework of clinical trials of the National Health System (NHS), and concerns 15 different types of cancer, including lung, breast, prostate and bladder cancer.
This specific method is based on the administration of the substance atezolizumab, a monoclonal antibody that helps the immune system identify and attack cancer cells. This substance was previously only administered intravenously in long-term sessions. Now, with the new subcutaneous administration technique, the process is completed in 5 to 7 minutes.
Scientists note that this method does not reduce the effectiveness of the treatment, while at the same time offering enormous advantages in terms of time, convenience and quality of life for patients.
This development is considered particularly important not only for the patients themselves, but also for health systems, as it allows for saving time and resources, while increasing accessibility to treatment.
The scientific community is optimistically watching the implementation of the new technique, which could be the next big step in the global fight against cancer.
